The Walter and Eliza Hall Institute of Medical Research
Breast and ovarian cancers can have a devastating impact on women, their family and friends, and the community. In recent years there have been encouraging improvements in the diagnosis and treatment of these cancers.
However, further research is vital to understand the complexities of cellular growth and interactions that cause breast and ovarian cancers to arise.
The Walter and Eliza Hall Institute of Medical Research are dedicated to finding novel approaches for prevention and treatment of breast and ovarian cancer.
Professors Geoff Lindeman and Jane Visvader are joint division heads of this breast cancer research laboratory, which is one of the most prestigious in Australia.
They oversee a formidable team of researchers who have made landmark discoveries in the prevention and treatment of breast and ovarian cancers.
There have been many exciting developments in Geoff and Jane’s research. A recent highlight has been the promising results from a trial to test Denosumab as a prevention for breast cancer in BRCA mutation carriers.
This resulted in $2.6 million in government funding for the first international trial for preventing breast cancer in woman carrying the BRCA1 gene mutation.
The remarkable success of this prevention research has promoted ideas for further studies – some that may have seemed too ambitious only a few years ago. This includes research into preventing ovarian cancer developing in BRCA mutation carriers. Geoff and Jane are also keen to deepen our knowledge of the development of cells in breast tissue using the latest single cell technology. This would help our researchers to identify unusual activity that may be causing cancerous cells to grow. With this knowledge, we would also be able to identify targets for potential new therapies.
Your support would greatly accelerate this research, as well as supporting a promising young breast cancer researcher to join the team to undertake a research fellowship.